

## AMENDMENTS TO THE CLAIMS

1-91. (Cancelled).

92. (Currently amended) A method of treating Huntington's disease in a human subject in need thereof comprising providing trophic support to striatal neurons by administering to the striatum of a subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4 and having cysteine residues at positions 7, 28, 59, 95, 148, 151, 161, 219, 243, and 265 relative to the amino acid sequence of SEQ ID NO: 4.

93-128. (Cancelled).

129. (Previously presented) The method of claim 92, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4.

130-131. (Cancelled)

132. (Currently amended) A method of treating Huntington's Disease in a human subject in need thereof comprising providing trophic support to

striatal neurons by administering to the subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence:

- having at least 95% identity to the amino acid sequence of SEQ ID NO: 4;
- having cysteine residues at positions 7, 28, 59, 95, 148, 151, 161, 219, 243, and 265 relative to the amino acid sequence of SEQ ID NO:4; and
- having all amino acid residues marked in Figure 3a as fully conserved(\*).

133. (Currently amended) The method of claim 132, wherein any mutation to an amino acid residue marked in Figure 3a as strongly conserved (:) is made within the following conserved groups: serine, threonine, and alanine; asparagines, glutamic acid, glutamine, and lysine; asparagine, histidine, glutamine, and lysine; asparagine, glutamic acid, aspartic acid, and glutamine; glutamine, histidine, arginine, and lysine; methionine, isoleucine, leucine, and valine; methionine, isoleucine, leucine, and phenylalanine; histidine and tyrosine; and phenylalanine, tyrosine, and tryptophan.

134. (New) A method of treating Huntington's disease in a human subject in need thereof comprising providing trophic support to striatal neurons by administering to the striatum of a subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4; wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 60.

135. (New) A method of providing trophic support to striatal neurons in a human subject in need thereof comprising administering to the striatum of a subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4; wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 60.

136. (new). The method of claim 92, wherein the neurotrophic polypeptide is capable of protecting striatal neurons against degeneration.